Key Points
- Indivior insider Christian Heidbreder sold 18,586 shares on July 10 at an average price of $41.14, for total proceeds of about $764,628. The sale reduced his direct holdings by 8.15% and was made under a pre-arranged Rule 10b5-1 plan.
- Indivior shares were down 0.7% in Tuesday trading, opening at $40.21. The stock has moved between a 52-week low of $15.00 and a high of $42.81, with a market cap of about $4.9 billion.
- Analysts remain moderately positive on Indivior, with six Buy ratings and two Hold ratings, and a consensus price target of $40.29. Recent coverage has been mixed, as Barclays initiated coverage with an overweight rating while other firms trimmed their views.
Indivior PLC (NASDAQ:INDV - Get Free Report) insider Christian Heidbreder sold 18,586 shares of the company's stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $41.14, for a total transaction of $764,628.04. Following the completion of the sale, the insider directly owned 209,337 shares of the company's stock, valued at $8,612,124.18. The trade was a 8.15% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Indivior Stock Down 0.7%
Shares of INDV opened at $40.21 on Tuesday. The firm has a market capitalization of $4.90 billion, a PE ratio of 20.62 and a beta of 0.86. The firm has a 50-day moving average price of $38.59 and a 200 day moving average price of $35.04. Indivior PLC has a 52-week low of $15.00 and a 52-week high of $42.81.
Indivior (NASDAQ:INDV - Get Free Report) last released its quarterly earnings results on Tuesday, March 31st. The company reported $0.96 EPS for the quarter. The company had revenue of $317.00 million for the quarter. Indivior had a net margin of 19.44% and a negative return on equity of 219.26%. On average, equities analysts expect that Indivior PLC will post 4.05 EPS for the current year.
Hedge Funds Weigh In On Indivior
Several hedge funds have recently made changes to their positions in the business. Hennion & Walsh Asset Management Inc. lifted its position in shares of Indivior by 43.4% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 317,600 shares of the company's stock valued at $11,395,000 after acquiring an additional 96,177 shares during the last quarter. Divisadero Street Capital Management LP boosted its stake in shares of Indivior by 2,372.5% during the 3rd quarter. Divisadero Street Capital Management LP now owns 3,362,605 shares of the company's stock worth $81,072,000 after acquiring an additional 3,226,605 shares in the last quarter. Goldentree Asset Management LP acquired a new position in shares of Indivior in the 3rd quarter worth $42,630,000. SG Americas Securities LLC grew its holdings in shares of Indivior by 752.2% in the 4th quarter. SG Americas Securities LLC now owns 412,197 shares of the company's stock worth $14,790,000 after acquiring an additional 363,829 shares during the last quarter. Finally, Yousif Capital Management LLC acquired a new stake in shares of Indivior during the fourth quarter worth $1,137,000. Institutional investors and hedge funds own 60.33% of the company's stock.
Wall Street Analyst Weigh In
Several equities research analysts recently commented on the company. Barclays began coverage on Indivior in a report on Thursday, June 18th. They set an "overweight" rating and a $46.00 target price on the stock. Weiss Ratings lowered Indivior from a "hold (c+)" rating to a "hold (c)" rating in a research note on Thursday. Finally, Zacks Research cut Indivior from a "strong-buy" rating to a "hold" rating in a research report on Monday, June 29th. Six equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, Indivior currently has a consensus rating of "Moderate Buy" and an average target price of $40.29.
Check Out Our Latest Stock Analysis on INDV
Indivior Company Profile
(
Get Free Report)
Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company's portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.
Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
